Platelet-derived growth factor enhances ex vivo expansion of megakaryocytic progenitors from human cord blood
Authors:
- 1 May 2001
- journal article
- research article
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 27 (10) , 1075-1080
Abstract
Infusion of ex vivo expanded megakaryocytic (MK) progenitor cells is a strategy for shortening the duration of thrombocytopenia after haematopoietic stem cell transplantation. The cell dose after expansion has emerged as a critical factor for achieving the desired clinical outcomes. This study aimed to establish efficient conditions for the expansion of the MK lineage from enriched CD34+ cells of umbilical cord blood and to investigate the effect of platelet-derived growth factor (PDGF) in this system. Our results demonstrated that thrombopoietin (TPO) alone produced a high proportion of CD61+CD41+ cells but a low total cell count and high cell death, resulting in an inferior expansion. The addition of interleukin-1β (IL-1β), Flt-3 ligand (Flt-3L) and to a lesser extent IL-3 improved the expansion outcome. The treatment groups with three to five cytokines produced efficient expansions of CFU-MK up to 400-fold with the highest yield observed in the presence of TPO, IL-1β, IL-3, IL-6 and Flt-3L. CD34+ cells were expanded by five to 22-fold. PDGF improved the expansion of all cell types with CD61+CD41+ cells, CFU-MK and CD34+ cells increased by 101%, 134% and 70%, respectively. On day 14, the CD61+ population consisted of diploid (86.5%), tetraploid (11.8%) and polyploid (8N–32N; 1.69%) cells. Their levels were not affected by PDGF. TPO, IL-1β, IL-3, IL-6, Flt-3L and PDGF represented an effective cytokine combination for expanding MK progenitors while maintaining a moderate increase of CD34+ cells. This study showed, for the first time, that PDGF enhanced the ex vivo expansion of the MK lineage, without promoting their in vitro maturation. PDGF might be a suitable growth factor to improve the ex vivo expansion of MK progenitors for clinical applications. Bone Marrow Transplantation (2001) 27, 1075–1080.Keywords
This publication has 33 references indexed in Scilit:
- Expression of interleukin (IL) 1 type I and type II receptors in megakaryocytic cells and enhancing effects of IL-1beta on megakaryocytopoiesis and NF-E2 expressionBritish Journal of Haematology, 2000
- Prompt and durable engraftment in two older adult patients with high risk chronic myelogenous leukemia (CML) using ex vivo expanded and unmanipulated unrelated umbilical cord bloodBone Marrow Transplantation, 2000
- Simultaneous cord blood transplantation of ex vivo expanded together with non-expanded cells for high risk leukemiaBone Marrow Transplantation, 1999
- A combination of megakaryocyte growth and development factor and interleukin-1 is sufficient to culture large numbers of megakaryocytic progenitors and megakaryocytes for transfusion purposesBritish Journal of Haematology, 1999
- Ex vivo expansion of enriched CD34+ cells from neonatal blood in the presence of thrombopoietin, a comparison with cord blood and bone marrowBone Marrow Transplantation, 1999
- Megakaryocyte progenitors derived from bone marrow or G‐CSF‐mobilized peripheral blood CD34+ cells show a distinct phenotype and responsiveness to interleukin‐3 (IL‐3) and PEG‐recombinant human megakaryocyte growth and development factor (PEG‐rHuMGDF)British Journal of Haematology, 1998
- Platelet-derived growth factor and alternative splicing: A reviewPathology, 1992
- Structural and functional aspects of the receptors for platelet-derived growth factorProgress in Growth Factor Research, 1989
- Platelet‐derived growth factor stimulates growth of highly enriched multipotent haemopoietic progenitorsBritish Journal of Haematology, 1986
- Platelet-derived growth factor promotes proliferation of erythropoietic progenitor cells in vitro.Journal of Clinical Investigation, 1983